|
Aims This study was designed to investigate the biochemical and
physiological covariates or comedications that affect the pharmacokinetics of
imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia (CP
CML). Methods Pharmacokinetic data were analyzed in 371 patients receiving 400
mg imatinib once daily during a phase III trial of imatinib vs interferon-alfa
plus cytarabine for the treatment of newly diagnosed CP CML.
|
[CML] A group of CMLHope.Com Subscribe: [EMAIL PROTECTED] Web Site: http://groups.cmlhope.com
